Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial

Next Previous
Trial Profile

An Open-label, Multi-center, Global, Rollover Study for Patients Who Have Previously Been Treated With Capmatinib (INC280) as Monotherapy or in Combination in a Novartis Sponsored Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capmatinib (Primary) ; Gefitinib; Nazartinib; Osimertinib
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 11 Apr 2024 This trial has been completed in France, according to European Clinical Trials Database.
  • 29 Sep 2022 Time frame for primary outcome increased from 5 years to 10 years. Osimertinib drug added newly to intervention.
  • 17 Jul 2020 Planned End Date changed from 31 Jul 2027 to 30 Jul 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top